UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma
Brief description of study
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Non-Hodgkins Lymphoma
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 832606
